Capstone Investment Advisors LLC acquired a new stake in shares of Apogee Therapeutics Inc. (NASDAQ:APGE – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 120,000 shares of the company’s stock, valued at approximately $15,928,000. Capstone Investment Advisors LLC owned about 0.19% of Apogee Therapeutics as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Rockefeller Capital Management L.P. bought a new stake in shares of Apogee Therapeutics in the fourth quarter worth about $25,000. Los Angeles Capital Management LLC bought a new position in Apogee Therapeutics during the fourth quarter valued at approximately $37,000. GAMMA Investing LLC boosted its stake in Apogee Therapeutics by 40.5% during the second quarter. GAMMA Investing LLC now owns 309 shares of the company’s stock valued at $41,000 after buying an additional 89 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Apogee Therapeutics by 61.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 645 shares of the company’s stock valued at $54,000 after buying an additional 246 shares in the last quarter. Finally, Longfellow Investment Management Co. LLC purchased a new position in Apogee Therapeutics during the 2nd quarter valued at approximately $81,000. Institutional investors own 79.04% of the company’s stock.
Insiders Place Their Bets
In related news, insider Carl Dambkowski sold 5,500 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $134.17, for a total value of $737,935.00. Following the completion of the sale, the insider directly owned 168,498 shares in the company, valued at $22,607,376.66. This trade represents a 3.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $133.63, for a total transaction of $2,672,600.00. Following the transaction, the chief executive officer directly owned 995,987 shares of the company’s stock, valued at $133,093,742.81. The trade was a 1.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 162,900 shares of company stock valued at $20,344,950. 24.30% of the stock is owned by corporate insiders.
Apogee Therapeutics Price Performance
Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.07). Equities research analysts expect that Apogee Therapeutics Inc. will post -4.47 EPS for the current year.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on APGE. Royal Bank Of Canada upped their price objective on Apogee Therapeutics from $82.00 to $97.00 and gave the stock a “sector perform” rating in a report on Monday, June 8th. BTIG Research lowered shares of Apogee Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, August 12th. UBS Group cut shares of Apogee Therapeutics from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $100.00 to $135.11 in a research report on Tuesday, June 23rd. The Goldman Sachs Group set a $89.00 price target on shares of Apogee Therapeutics in a research note on Thursday, May 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $126.77.
View Our Latest Research Report on Apogee Therapeutics
Apogee Therapeutics Company Profile
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Read More
- Five stocks we like better than Apogee Therapeutics
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
